Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02279394
Title Trial of Combination of Elotuzumab and Lenalidomide +/- Dexamethasone in High-Risk Smoldering Multiple Myeloma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

smoldering myeloma

Therapies

Dexamethasone

Elotuzumab + Lenalidomide

Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
Colorado Blood Cancer Institute Denver Colorado 80218 United States Details
St Francis Hospital and Medical Center Hartford Connecticut 06105 United States Details
University of Chicago Chicago Illinois 60637 United States Details
Eastern Maine Medical Center Brewer Maine 04412 United States Details
University of Maryland Baltimore Maryland 21201 United States Details
Massachusetts General Hospital Boston Massachusetts 02114 United States Details
Dana-Farber Cancer Institute Boston Massachusetts 02215 United States Details
Barbara Ann Karmanos Cancer Institute Detroit Michigan 48201 United States Details
Levine Cancer Institute Charlotte North Carolina 28204 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field